University of Michigan Hemophilia and Coagulation Disorders Program, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, USA. Email: email@example.com
Haemophilia Centre, Great Ormond Street Hospital for Children NHS Trust, Great Ormond St, London WC1N 3JH, UK.
Phoenix Healthcare, Parkshot House, 5 Kew Road Richmond, London TW9 2PR, UK.
The Children’s Hospital at Westmead, Locked Bag 4001, Westmead 2145, New South Wales, Australia.
Haemophilia Centre, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK.
Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark.
Novo Nordisk Health Care AG, Thurgauerstrasse 36, 8050 Zürich, Switzerland.
Prophylactic coagulation factor replacement is increasingly the treatment modality of choice for people with haemophilia (PWH). Currently available recombinant factor products require reconstitution from a lyophilised powder and diluent, and a range of infusion systems is available to assist in this process. This study aimed to understand the properties of a reconstitution/infusion system that are most important to PWH and carers of children with haemophilia (CWH), and to assess two available systems produced by Novo Nordisk for the reconstitution and infusion of activated recombinant factor VII and recombinant factor VIII: the original infusion system and the newer MixPro® system. Both were tested by a group of 67 PWH or carers of CWH who were naïve to them. Participants rated the performance of each system against 18 predefined parameters using the 7-point Likert scale, and ranked the importance of these parameters to the design of an infusion system. They also directly compared the performance of the two systems and provided qualitative feedback. Overall, MixPro® was preferred to the original system by 94% of study participants. This was reflected in the performance scores for individual parameters, with scores in 16/18 parameters being significantly higher for MixPro® (p<0.05) than the original system. Low contamination risk was seen as the most important criterion in the design and choice of an infusion system, with 97% regarding MixPro® as the superior system in this category. The MixPro® system was perceived as being quick, easy to use, convenient and portable. It is hoped that these findings may help guide the future design of infusion systems for PWH.
Editorial assistance in the preparation of this manuscript was provided by AXON Communications, and was financially supported by Novo Nordisk in compliance with international guidelines for good publication practice. The research described in this article was undertaken by Phoenix Marketing International and funded by Novo Nordisk Health Care AG, Zürich, Switzerland.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The Journal of Haemophilia Practice is published by Haemnet.
Haemnet is a registered charity that brings together and gives a voice to haemophilia nurses, physiotherapists and allied health care professionals, providing forums for collaborative research, educational activities and support.